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Abstract  
Antibody-drug conjugates (ADCs) have emerged as a promising class of anti-cancer 
agents, combining the specificity of antibodies for tumor targeting and the destructive 
potential of highly potent drugs as payload. An essential component of these 
immunoconjugates is a bifunctional linker capable of reacting with the antibody and the 
payload to assemble a functional entity. Linker design is fundamental, as it must provide high 
stability in the circulation to prevent premature drug release, but be capable of releasing the 
active drug inside the target cell upon receptor-mediated endocytosis. Although ADCs have 
demonstrated an increased therapeutic window, compared to conventional chemotherapy in 
recent clinical trials, therapeutic success rates are still far from optimal. To explore other 
regimes of half-life variation and drug conjugation stoichiometries, it is necessary to 
investigate additional binding proteins which offer access to a wide range of formats, all with 
molecularly defined drug conjugation. Here, we delineate recent progress with site-specific 
and biorthogonal conjugation chemistries, and discuss alternative, biophysically more stable 
protein scaffolds like Designed Ankyrin Repeat Proteins (DARPins), which may provide such 
additional engineering opportunities for drug conjugates with improved pharmacological 
performance. 
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1. Introduction  
The fundamental problem of all chemotherapeutic agents is their small therapeutic window. 
While most compounds in use today preferentially attack proliferating cells, classical 
chemotherapy causes side effects which limit the tolerated doses below the clinically effective 
ones. To increase the therapeutic window, dose-limiting toxicity must be reduced while at the 
same time effectiveness must be maintained. Antibody-drug conjugates (ADCs) combine the 
unique specificity of antibodies for tumor-associated antigens to discriminate between normal 
and malignant cells, and the cytotoxic effect of a small molecule drug as payload 1-3 . 
Nonetheless, far from being a magic bullet, ADCs normally will have several liabilities as 
well: on-target, by the target antigen being expressed in healthy tissues, and off-target, on the 
one hand by an unspecific uptake of the whole conjugate by healthy cells, and on the other, by 
the drug coming off the antibody. Additionally, the high specificity offers an escape 
mechanism to the tumor cells by down-regulating the relevant surface antigen 4. These 
general considerations emphasize the importance of a judicious choice of the target antigen 
for minimizing on-target toxicity, while molecular engineering optimizing half-lives and 
general molecular properties is needed for minimizing off-target toxicity of the conjugate. 
Finally, linker chemistries must be considered to optimize toxin release after cellular uptake, 
but not prematurely. 
The first cytotoxic agents used for antibody payloading were vinblastine, doxorubicin, 
methotrexate, and melphalan. In the most promising of these first-generation ADCs, 
doxorubicin was attached to the anti-Lewis Y antibody BR96, using an acid-labile hydrazone 
bond. Despite impressive effects in tumor xenograft models 5, BR96-doxorubicin, however, 
demonstrated very low antitumor activity and tolerability in patients 6, 7. Binding of the 
antibody to normal epithelial tissues, low drug potency, and insufficient stability of the 
conjugate were made responsible for the clinical failure of this first-generation ADC. In the 
meantime, the spectrum of tumor-selective antigens has increased and more potent anti-cancer 
agents with cellular IC50 values in the pM range have become available for antibody 
payloading 2. 
Another important element in ADC design is the choice of the linker which connects 
the chemically different targeting molecules to a functional chemical entity and maintains the 
distinct biological functions of the components. To provide high potency and tolerability, the 
linker must be stable to prevent premature drug release in the circulation but capable of 
releasing it inside the cell upon receptor-mediated endocytosis, such that the (usually) 
4 
 
hydrophobic drug can cross the endo-lysosomal membrane into the cytosol. Currently, two 
categories of linkers, cleavable and non-cleavable, are used, which address these requirements 
by different mechanisms 2. The next crucial step is then to attach the linker-drug constructs to 
specific reactive sites in the antibody.  
With common antibodies, conjugation is possible at lysines, cysteines or N-glycans. 
The conjugation at lysines, considering the large number in an IgG, will be stochastic and 
result in heterogeneous synthetic products characterized by variable drug-antibody ratios 
(DARs), at least over a certain range. The conjugation at cysteines can either be to disulfides 
(typically at the hinge), which need to be reduced first, or to genetically introduced cysteines 
8. While reaction conditions have been optimized to obtain desired DARs, pharmacological 
performance may well depend not only on the DAR, but also on the precise location of the 
drug on the binding protein 9. 
Recent biotechnological advances have provided a multitude of protein modification 
strategies to better fix the number and location of payload attachment in ADCs 8, 10. Also, a 
number of enzymatic conjugation strategies have been reported that allow the attachment of 
the drug to a tag introduced to the antibody 11. In addition, alternative non-IgG formats have 
become available, which can be engineered to a variety of half-lives, expressed at very high 
yields and better tolerate the engineering procedures required for well-defined DARs and 
optimal efficacy 12, 13. Here, we delineate recent progress in ADC design and the perspectives 
for engineering novel tailor-made drug-conjugated binding protein formats with desired 
pharmacological properties.  
2. Clinical benefit for tumor-targeting ADCs  
Owing to a better understanding of the pharmacological determinants of tumor 
targeting and recent progress in protein engineering, bioconjugation chemistries and the 
generation of highly potent payloads, the ADC pipeline is rapidly growing with currently 
more than 100 entities in clinical trials. For oncology indications, however, clinical results are 
still far from exciting and many challenges remain to help this technology establish its place 
in cancer therapy (www.clinicaltrials.gov).  
ADCs approved by the US Food and Drug Administration (FDA) or currently in 
advanced clinical trials are shown in Table 1. So far, only three ADCs were approved by the 
FDA. They employ either the tubulin polymerization inhibitors monomethyl auristatin E and 
F (MMAE, MMAF), derivatives of maytansine or the DNA-strand breaking calicheamicin 
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(Table 1). These payloads outperform the potency of classical chemotherapeutic drugs by a 
factor of 1000 2. As the first, gemtuzumab ozogamicin (Mylotarg®), which consists of an anti-
CD33 antibody linked to calicheamicin, was granted accelerated approval in 2000 for the 
treatment of relapsed acute myeloid leukemia (AML) 14. It was withdrawn from the market 10 
years later, due to excessive toxicity and lack of anti-tumor activity in a post-approval clinical 
trial with newly diagnosed AML 15. Since then, several randomized studies have been 
completed which nevertheless demonstrate efficacy of this ADC for the same indication using 
a modified dosing regimen 16. It may well be that gemtuzumab ozogamicin will soon find 
reapproval for this disease. However, this history impressively shows how narrow the 
therapeutic window in ADCs really can be, and that clinical reality can be very different from 
seemingly straightforward concepts. 
The next approved candidate was brentuximab vedotin (Adcetris®), an anti-CD30-
MMAE immunoconjugate, which obtained accelerated FDA approval for the treatment of 
Hodgkin's lymphoma and anaplastic large cell lymphoma in 2011 17. In 2013 finally, ado-
trastuzumab emtansine (T-DM1/Kadcyla®), an ADC combining an anti-HER2-antibody with 
the maytansinoid DM1, obtained market approval for the treatment of HER2-positive 
metastatic breast cancer (Table 1) 18. However, the recently reported failure of Kadcyla® to 
meet the primary endpoint of a phase III study in breast cancer patients (NCT01120184; 
BO22589) denotes an unpleasant setback in the field. A deeper understanding of the intrinsic 
properties of the distinct functional components is key to more successful ADC design in the 
future and to improve the perspectives of the whole ADC concept for cancer therapy.  
3. Linker chemistries  
One critical component of the ADC entity is the linker tethering the cytotoxin to the 
antibody. To achieve a maximal therapeutic window, it must be stable in the circulation, yet 
allow efficient drug release inside the cell upon receptor-mediated endocytosis. Therefore, it 
must exploit the differences between the extra- and intracellular environment, respect the 
properties of the target antigen for internalization and must be compatible with the chemistry 
of the payload. Linker design, hence, does not follow predefined guidelines and needs to be 
determined empirically for each ADC 2, 3.  
Currently used linkers in ADCs are either cleavable or non-cleavable 1. Payloads not 
tolerating substitutions without loss of activity require cleavable linkage which depends on 
intracellular processing such as acidic hydrolysis or enzymatic cleavage in the endo/lysosome, 
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leading to release and thus activation of the drug. This allows bystander killing of non-
targeted tumor cells when hydrophobic drugs are used, which is particularly advantageous if 
antigens are heterogeneously expressed in tumors 19. Acid-labile hydrazone linkers were 
among the first cleavable linkers used in ADCs. Upon internalization, the acidic pH in 
endosomes (pH 5.0-6.5) and lysosomes (pH 4.5-5.0) leads to hydrolysis of the hydrazone and 
subsequent release of the drug 2, 20. The serum stability of hydrazone linkers, however, is poor 
21, 22. The low clinical efficacy and the safety concerns of gemtuzumab ozogamicin were 
mainly attributed to this linker instability and premature drug release in the circulation 5, 16, 23. 
Cleavable disulfide linkers, in turn, exploit the high concentration of thiols, such as 
glutathione, in the cytoplasm, which reduce a disulfide bond in the linker to liberate the 
payload 1, 24. To decrease reduction by reactive thiols in the serum, the stability of disulfides 
can be increased by introducing methyl groups flanking the disulfide bond to generate a 
sterically protected disulfide linker 25. Although several disulfide-linked ADCs are currently 
under clinical investigation (Table 1), more stable cleavable linkers are engineered in the form 
of lysosomal protease substrates, e.g. containing a valine-citrulline dipeptide bond, which is 
specifically cleaved by cathepsin B 26-28. 
Non-cleavable linkers, on the other hand, avoid premature drug release in the 
circulation by design 1. Instead, the ADC must be proteolytically degraded in lysosomes and 
the payload is released as an active metabolite along with the amino acid it was conjugated to, 
i.e., usually a cysteine or lysine 19, 29. Although the charge of a lysine-Nε-coupled drug 
metabolite may hamper endo-lysosomal escape, it prevents externalization and bystander 
killing 29, 30. This will, on the one hand, lead to enhanced specificity, but on the other hand, 
limit the action of the drug to the very cell that has taken up the ADC. 
Furthermore, as the linker forms part of the active drug, it can be designed to add 
additional valuable functional properties to the drug, like prevention of MDR1 efflux and thus 
drug resistance, by making it more hydrophilic, e.g., in the form of a PEG4Mal linker 31.  
4. Payloads  
Natural products and synthetic chemistry provide a plethora of cytotoxins of which 
only few have been found suitable for use in ADCs 32, 33. First, the drug’s target must be 
crucial for cell viability to achieve highest cytotoxicity even at the low concentrations which 
can be realistically achieved upon internalization. Ideally, the number of drug molecules 
required to kill a cell are well below the number which is delivered by ADCs, that depends on 
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the DAR and the number of ADCs taken up by a cell in a clinical setting. Data using 
radiolabeled humanized antibodies suggests that localization in tumors does not exceed 0.05% 
of the injected dose per gram tissue 2, 34. This, in turn, leads to the unavoidable conclusion that 
the vast majority of the ADC does not end up in tumor cells. 
Drug activation depends on the linker chemistry and occurs after cleavage or by 
lysosomal degradation 1. To show selectivity upon antigen-specific uptake, the payloads’ 
target must be located inside the tumor cell. Many highly potent natural toxins act on the 
surface of cells by blocking ion channels, disturbing blood clotting etc. and are thus 
unsuitable, as cell specificity would not be achievable by a conjugated antibody. On top of 
that, the payload's molecular properties are important, too. It must be small in size to reduce 
immunogenicity, soluble under aqueous conjugation conditions to prevent aggregation, and 
compatible with the linker chemistry 35.  
Consequently, as mentioned above, all ADCs approved or under late clinical 
investigation are payloaded with new generation drugs dominated by the DNA-strand 
breaking calicheamicins 25, 36, 37, duocarmycins 38, the tubulin-targeting maytansines 39, 40 and 
auristatins 17, 41. The mechanisms of action and the chemistry of the coupling and release 
reactions of these warheads have been described in detail elsewhere 1, 42, 43. Table 1 
summarizes representative examples of clinically advanced ADCs using these highly potent 
drugs as payloads. 
5. Conjugation chemistries  
5.1. Site-selective conjugation and the drug to antibody ratio  
Conjugation site-selectivity and stoichiometrically controlled conjugation of cytotoxic 
payloads to antibodies and other non-IgG binding proteins is crucial for tumor targeting. So 
far, all chemistries used for linker-drug conjugation to antibodies in late clinical trials have 
been based on solvent accessible cysteine and lysine residues through either thiol-maleimide 
coupling (e.g. brentuximab vedotin) 17 or amine NHS-ester coupling (e.g. ado-trastuzumab 
emtansine) 44, respectively (Table 1 and Table 2). As IgGs carry a variable number of lysine 
side-chains, this yields heterogeneous products with variable DARs and inter-batch variations. 
For instance, a typical modification of an IgG with an NHS-ester yields an average DAR of 0-
8. Thus, the 40-86 lysine residues on the antibody surface are modified to a variable degree, 
resulting in a sample with potentially 4.5 million different molecules in terms of 
regioisomerism and drug load 45, 46. If thiol-maleimide coupling is used instead, cysteine 
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conjugation occurs after mild reduction of the four inter-chain disulfide bonds in the hinge 
region of an IgG1. Although conjugation is limited to these eight exposed sulfhydryl groups, 
as clinically used IgG1 typically do not have Cys residues in the CDRs, and thus a higher 
coupling specificity compared to lysines can be achieved, it can still yield more than hundred 
different ADC species 46, 47, depending on the degree of loading and considering regioisomers. 
It must be noted that both DAR and conjugation sites are important for ADC function, as they 
influence the molecular properties through the exposed drug moiety. Whereas a drug load of 2 
seems to provide the best pharmacological performance 47, the site of drug conjugation 
determines linkage stability and thus the ADC's tolerability and efficacy 9.  
As a consequence of the limited site-selectivity of drug conjugation with conventional 
linkage strategies, even the clinically approved ADCs represent mixtures of regioisomers with 
different DARs, each of the molecular species showing a different cytotoxicity and safety 
profile 47, 48. Unconjugated antibodies, which can be hardly separated from the preparations, 
block potential binding sites on the tumor surface and thus lower ADC efficacy, whereas drug 
conjugates with high DAR show increased off-target toxicity and are prone to aggregation, 
which narrows the therapeutic window 49. This delineates that current ADC design is still far 
from optimal. To engineer ADCs for higher efficacy and tolerability, site-selective 
conjugation is mandatory to better control the number and attachment site of payloads.  
Recently, Pillow et al. 48 reported a markedly improved homogeneity of trastuzumab-
DM1 generated by engineering cysteine residues at defined sites in the antibody. Since the 
exposed cysteines are derivatized with cysteine or glutathione in the secretory pathway of the 
host cell, a reduction/oxidation process is required (THIOMAB technology), which reforms 
the hinge and CL-CH disulfides 50. The better defined DAR of 2 to 4 and a novel linker 
technique for DM1 increased the efficacy and safety of the resulting ADC 48. This must be 
seen in the context of recent findings that in terms of efficacy, less payload is more 47.  
Another technique to site-specifically conjugate payloads to antibodies is the use of N-
glycans for attachment. Major limitations of this technique, however, are the difficulty to 
obtain homogeneous glycan structures and to avoid unwanted oxidations of the proteins 
resulting from chemical modifications. Furthermore, the glycan structure is important for 
desired antibody functions like ADCC and, when modified, can generate new highly 
immunogenic epitopes 8. 
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5.2 Bioorthogonal conjugation  
In view of the many downsides associated with uncontrolled payloading, engineering 
a unique, orthogonal functional group into proteins, which then can be coupled to a specific 
reaction partner in a bioorthogonal manner, is appealing also for antibody drug conjugation. 
In this constellation, two components, which are fully complementary and, additionally, 
orthogonal to nature’s functional groups on protein (thiols, alcohols or amines), react to form 
a chemical bond. These components must be stable and small, whereas the reaction must be 
fast, and yet conditions must be so mild that the reaction can be conducted with proteins 51. 
The concept of orthogonal chemistry aims to avoid unspecific side-reactions and allows 
stoichiometrically defined modifications. Here, we briefly discuss the various biorthogonal 
conjugation chemistries with potential for ADC generation. The use of enzymes, either for the 
conjugation reaction itself or the incorporation of unique functional groups into proteins, also 
represents a valid concept for drug conjugation, the benefits and drawbacks of which are 
described elsewhere 8, 11, 51.  
The first truly bioorthogonal reaction for protein modification was reported in 2000 
using the Staudinger ligation. Derived from the original Staudinger reaction, a reaction 
between a phosphine and an azide leading to an amine by subsequent hydrolysis, was 
modified to form a stable amide bond linkage 52, by installing an electrophilic trap at the 
phosphine component. A significant drawback of this ligation reaction is the oxygen 
sensitivity of the phosphine reagents and the slow reaction rate constant, and thus it is not 
well suited for conjugation of drugs to protein and not used nowadays.  
5.3 Click chemistries for bioconjugation  
Another approach to biorthogonal protein modification exploits the 1, 3-diploar 
cycloaddition for linking biological components. In this Cu(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC) an azide reacts with a terminal alkyne to form a stable triazole 
(Table 2) 53, 54. The higher reaction rate and the stability of the reactants has made this 
reaction appealing and widely used for bioconjugation 55. Its dependence on cytotoxic copper, 
however, limits the use of such products in biological systems. A copper-free alternative is the 
strain-promoted azide-alkyne cycloaddition (SPAAC), also denoted click chemistry, which 
uses ring-strained cyclooctynes instead of terminal alkynes (Table 2) 56. To improve the 
moderate reaction rates, various derivatives such as fluorinated 57, benzoannulated 58, 59 and 
cyclopropanated 60 cyclooctynes, have been synthesized. Noteworthy are the cyclopropanated 
variant bicyclo[6.1.0]nonyne (BCN) and the benzoannulated derivative dibenzocyclooctyne 
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(DBCO), also denoted as aza-dibenzocyclooctyne (DIBAC). Both reactants improve reaction 
rates 100-fold over cyclooctyne. Altogether, DBCO was found to best combine high stability 
and efficiency with high hydrophilicity and fast reaction kinetics for the classical SPAAC 
reaction. 
For protein-drug conjugation, it would be most appealing if the site of drug 
conjugation in the protein can be freely chosen. This is the case with non-natural amino acids 
containing azides as they can replace methionines. The aminoacyl tRNA synthase for 
methionine in E. coli accepts the methionine-surrogate azidohomoalanine (Aha), and thus in 
methionine-auxotrophic E. coli strains, after simple Met depletion of the culture, Aha can be 
introduced without any other changes in the E. coli strain 61. However, this requires that the 
protein can be produced in E. coli and thus this strategy favors alternative non-IgG scaffolds. 
Nevertheless, despite the use of rate-optimized cyclooctynes like DBCO and BCN, the 
described reactions are comparably slow (0.1 - 0.3 M-1s-1), and unspecific coupling to 
irrelevant reaction partners present on cell surfaces cannot be excluded and limit the 
orthogonality of the reaction 59, 60, 62. On the other hand, as bioconjugation partners of ADCs 
are usually very pure, such side reactions are unlikely to occur and the stability of the 
components used for cycloaddition remains as an advantage.  
The rate constant of SPAAC with BCN can be highly accelerated using electron-poor, 
aromatic azide components instead of Aha 63. In another study, Borrmann et al. 64 reported 
even more improved rates of cycloaddition by several orders of magnitude using quinones 
instead of azides as reaction partner for BCN. Moreover, this reaction can be temporally 
controlled by oxidation of inert catechols to the reactive quinone. To make these reactions 
applicable to proteins, they must first be charged with aromatic azides, BCN or quinones in a 
stoichiometrically defined, site-specific manner. This no longer possible with a simple met– 
strain of E. coli, but requires amber-suppression technology for site-specific incorporation of 
BCN-lysine or other non-natural amino acids carrying functional groups like quinones or 
norbonenes 65-72. So far, this technology was only used for imaging agents, as it shows 
unfavorably low expression yields 66.  
Also in our hands, amber suppression protein variants showed comparatively low 
expression and also inhomogeneity, since the efficiency of suppression varies with the amber 
site. This requires engineering for purification and thus limits the freedom of molecular 
design (unpublished data). Although this may in principle be overcome using sequence 
optimization 73 and adapted E. coli strains 74, the problem remains that, compared to azide-
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containing non-natural amino acids like Aha, non-natural amino acids like BCN-lysine are 
rather expensive, and, to our knowledge, bacterial strains and vectors carrying tRNA/RS pairs 
for the incorporation of specific non-natural amino acids have not been made commercially 
available.  
Using the amber suppression technology to site specifically incorporate para-
acetylphenylalanine (pAF) in antibodies and to conjugate the drug payload via oxime ligation 
(Table 2) 10, 75, 76, new biologicals could be generated. This technology, when applied to 
trastuzumab emtansine, yields a defined DAR of 2, and the authors believe that the antitumor 
activity and stability is increased compared to drug conjugates produced with the THIOMAB 
method. A possible explanation might be that a retro-Michael addition, leading to the transfer 
of drugs conjugated to cysteines to free thiols in blood serum components, may have partially 
inactivated the ADC 76-78. However, the authors do not provide convincing data showing that 
their own preparation of the THIOMAB antibody had a DAR of 2, as it was published by 
Junutula et al. 50. Furthermore the pAF incorporation still suffers from low expression yields, 
which can only be overcome by extensive cell line engineering, and the oxime ligation 
exhibits low reaction rates, leading to reaction times up to 48 h and is performed at pH 4-4.5, 
which is not tolerated by all proteins.  
5.4 The inverse-electron-demand Diels-Alder reaction for bioconjugation  
The highest rate constants of bioconjugation can be achieved by using the inverse-
electron-demand Diels-Alder reaction of tetrazines and strained alkenes for bioconjugation 79. 
As it has been reported only recently, this results from a decreased closed-shell electron-
electron repulsion between the reaction partners 80. Nothing beats rate constants of up to 106 
M-1s-1 of s-tetrazines with trans-cyclooctene (TCO)-derivatives (Table 2). Since TCO and 
tetrazines can be incorporated in proteins using amber-suppression, numerous applications for 
imaging purposes were reported 72, 81, 82. A downside lies in the diminished stability of the 
most reactive tetrazines in physiological buffers, and, as mentioned above, broad use of the 
amber-suppression-technique is still limited by the high costs of the reagents, low expression 
yields and restrictions in where the modification site can be introduced. Nonetheless, if these 
obstacles can be overcome, the value of this protein payloading technique for ADC generation 
would be immense. 
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6. Binding proteins – antibodies and alternative non-IgG formats 
The key function of the antibody in ADCs is binding to its target antigen, which is 
ideally expressed on the surface of tumor cells in high copy numbers and absent or at least 
low in normal vital tissues. Upon binding, the attached payload is delivered into the cell by 
receptor-mediated endocytosis, detached from the antibody by a variety of mechanisms, and 
transferred to the cytosol, where it acts on its target. An intrinsic property of the full-IgG 
format is its binding to Fc receptors on immune effector cells, which may further boost the 
ADC's cell killing activity. The clinical benefit of this additional effector function, however, 
remains to be demonstrated 49. In addition, binding to the FcRn receptor increases the 
circulation half-life and, hence, tumor localization. However, the comparison of a diabody-
ADC with an IgG-ADC with similar DARs showed only a 3-fold decreased antitumor activity 
of the diabody-ADC, despite a 30-times lower level of exposure 83. The improved tumor 
penetration of smaller conjugates may at least partly compensate the shorter serum half-life 
and thus help explain this finding 49.  
From these data it can be concluded that, by engineering half-life, size, avidity or 
other properties of different binding protein formats over a wide range, which is not possible 
with classical IgGs, the best combination of high activity in the relevant (tumor) tissue and 
low off-target toxicity can be found. Another important advantage of smaller protein 
scaffolds, especially when they can be produced in E. coli, lies in the broader options for 
well-defined drug conjugation, which may be a downside of the classical IgG format.  
Fab- and scFv-ADCs can be engineered for drug conjugation, and indeed, with such 
size-minimized IgG binding proteins, DARs of 1 have been achieved and several IgG-
fragments are currently under preclinical evaluation 49. Axup et al. 84 recently generated a 
highly potent Fab-auristatin using amber suppression for the incorporation of pAF and oxime 
ligation for drug conjugation. Novel biorthogonal chemistries like click chemistry or the 
inverse-electron-demand Diels-Alder reaction, however, have not yet been applied to 
antibody fragments. Hence, non-IgG derived binding proteins allowing the application of new 
bioorthogonal chemistries for fast and site-specific drug conjugation with high yields and 
permitting the screening of a wide range of pharmacological and molecular properties, are 
desired.  
As an alternative to antibodies and their fragments, various non-IgG binding proteins 
with improved biophysical properties have been generated for tumor targeting. Their robust 
nature allows expression in large quantities, they can be engineered to various formats, from 
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mono-, bi- to tetravalent, and with a range of half-life extension features, and they can better 
tolerate the introduction of reactive groups for site-specific and bioorthogonal conjugation 12, 
85. These properties introduced in the design also make these formats compatible with the 
novel bioorthogonal conjugation chemistries described above. Despite this advantage for 
bioconjugate engineering, so far only DARPins have been used for drug conjugation 86. The 
potential of bioorthogonally assembled peptide-drug conjugates for tumor targeting is 
described elsewhere 87.  
DARPins have been introduced recently as a new class of binding proteins which are 
superior to antibodies for various biomedical applications 13. Besides showing very high 
expression yields in E. coli, DARPins are much more stable than antibodies and have 
favorable biophysical properties which increase their freedom of engineering as they e.g. 
carry no cysteine and no essential methionine 88. Moreover, DARPins of very high affinity 
can be readily generated using well-established selection techniques such as ribosome display 
and phage display as previously demonstrated 13. We recently described the successful 
generation and preclinical testing of DARPins selected for high stability and affinity, directed 
against well-internalizing cell surface antigens on solid tumors, which are available for tailor-
made drug conjugation 89-91. 
DARPins provide a valuable platform also for manufacturing bioconjugates with 
various chemistries. First, the lack of native cysteines enables site-directed introduction of 
these residues, e.g. at the C-terminus for specific maleimide-based conjugation of effector 
functions, including the cytotoxic payloads known from classical ADCs (Figure 1). Of 
particular interest for drug conjugation of DARPins is also the lack of conserved methionines 
in the protein scaffold. This allows for the facile incorporation of Aha and the expression of 
azide-DARPins using methionine-depleted bacterial cultures 61, 85, which can be done in very 
high yield and at large scales. The only Met present in the original design, besides the initiator 
codon, is in the N-capping repeat, which can be exchanged to leucine without affecting the 
biophysical properties of the protein and is already replaced in some DARPins through the 
random mutagenesis in ribosome display 85. Additionally, DARPins are usually expressed 
with an N-terminal MRGSH6 tag, from which the methionine is not cleaved 92, and this is also 
true when an amino acid analog is introduced 93. Conversely, if the second amino acid is small 
(e.g., Ala, Gly or Ser), the analog will be cleaved off, allowing the introduction of a unique 
methionine surrogate such as Aha at desired positions elsewhere in the chain (Figure 1) 85. 
The possibility to engineer dual functionality (azide and thiol) into DARPins enables the 
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design of tailor-made drug conjugates with desired pharmacological properties, e.g. by site-
specific payloading with a cytotoxin like MMAF and additional coupling of a half-life 
extension module like serum albumin 86. Such a conjugate demonstrated nanomolar potency 
in vitro and a hundred-fold increased serum half-life. This is the first evidence that alternative 
binding proteins like DARPins are very compatible with the advanced bioorthogonal 
conjugation chemistries and can be engineered further to optimize the pharmacological 
properties of the targeting molecules. Importantly, not only the half-life can be engineered but 
also bispecific binding proteins can be easily designed from such scaffolds, allowing the 
optimization of drug conjugate performance for tumor targeting 94. 
7. Conclusion and perspective  
ADCs combine the specificity of antibodies for tumor-associated antigens to 
discriminate between normal and malignant cells, and the cytotoxic effect of novel drug 
agents as payload. The choice of the linker design is crucial for potency and tolerability as it 
determines stability of the ADC and the site where the drug is released and activated. Despite 
intensive research in these fields and a growing number of candidates in clinical trials, so far 
only two ADCs have been granted approval for oncology indications, indicating that there is 
still ample space for improvements. Clearly, in the parameter space between choice of target, 
optimal half-life, maximal target-tissue toxicity and minimal systemic toxicity, optima are not 
so easily found, as all parameters are mutually dependent on each other. Nonetheless, for 
every molecule, defined conjugation and regiochemistry are important components. For 
whole antibodies, engineered cysteine sites (THIOMAB technology) and the incorporation of 
pAF with amber suppression technology are two methodologies addressing this problem, each 
with its own strengths and weaknesses. 
For site-specific, stoichiometrically defined and fast drug conjugation, proteins can 
now be engineered to contain non-native functional groups to perform novel bioorthogonal 
reactions. Such alternative binding proteins, e.g. DARPins, are very compatible with the 
novel biorthogonal conjugation chemistries for payloading and can be engineered for variable 
half-life, avidity and bispecificity. They hold promise to establish a new generation of 
functionally improved drug conjugates for cancer therapy as a broad range of desired 
pharmacological and biophysical functions can be readily introduced into these binding 
proteins.  
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Figure 1: Double functionalized DARPin (blue) for bioconjugation of effector modules (R1 
and R2) at defined positions in the DARPin scaffold.  
A unique azidohomoalanine (pink) and cysteine (green) can be introduced at any position for 
bioconjugation by click or thiol chemistry, respectively, for producing stoichiometrically 
defined DARPin-cytotoxin bioconjugates. The position of azidohomoalanine and cysteine can 
be moved to any desired position in the DARPin scaffold, and they are shown at the termini 
merely for clarity. Figure adapted from 85. 
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ADC Drug Linker Coupling reaction Antigen Lead indication 
Approved       
Brentuximab vedotin 
(Adcetris®) 
MMAE Valine-citrulline Cys + maleimide CD30 HL, ALCL 
Ado-trastuzumab 
emtansine (Kadcyla®) 
DM1 Thioether Lys + NHS (SMCC) Her2 Breast cancer 
Phase III      
Gemtuzumab ozogamicin Calicheamicin Hydrazone Lys + AcBut CD33 AML 
Inotuzumab ozogamicin Calicheamicin Hydrazone Lys + AcBut CD22 ALL, NHL 
Brentuximab vedotin 
(Adcetris®) 
MMAE Valine-citrulline Cys + maleimide CD30 HL, T-cell lymphoma 
Ado-trastuzumab 
emtansine (Kadcyla®) 
DM1 Thioether Lys + NHS (SMCC) Her2 Gastric cancer, Breast 
cancer 
Phase II      
Glembatumumab vedotin MMAE Valine-citrulline Cys + maleimide gpNMB Breast cancer, Melanoma 
Pinatuzumab vedotin MMAE Valine-citrulline Cys + maleimide CD22 NHL 
Polatuzumab vedotin MMAE Valine-citrulline Cys + maleimide CD79b B-cell lymphoma 
SAR3419 DM4 Disulfide Lys+ NHS (SPDP) CD19 B-cell lymphoma 
Lorvotuzumab mertansine DM1 Disulfide Lys + NHS (SPP) CD56 aSCLC 
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Table 1: ADCs FDA-approved or currently in advanced clinical trials (www.clinicaltrials.gov).  
AcBut, 4-(4'-acetylphenoxy) butanoic acid; ALCL, Anaplastic Large Cell Lymphoma; ALL, Acute Lymphoblastic Leukemia; AML, 
Acute Myelogenous Leukemia; HL, Hodgkin's Lymphoma; NHL, Non-Hodgkin Lymphoma; NHS, N-hydroxysuccinimide; SCLC, Small 
Cell Lung Cancer; SMCC, succinimidyl-4-(N-maleimidomethly)cyclohexane-1-carboxylate; SPDP, succinimidyl 3-(2-
pyridyldithio)propionate; SPP, N-succinimidyl 4-(2-pyridyldithio)pentanoate 
aHalted 
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Reaction 
Chemistry Reaction scheme 
Reaction
Rate 
Conjugation Site in 
Protein 
Incorporation 
Method 
Amine-NHS 
 
fast Lysine, terminal amine Natural 
Thiol-Maleimide 
Michael Addition 
 
fast Cysteine Natural 
Oxime Ligation 
 
slow p-Acetylphenylalanine Amber suppression 
Cycloaddition 
CuAAC 
 
slow Azidohomoalanine 
Methionine - 
auxotrophic 
E.  coli 
Cycloaddition  
SPAAC 
 
slow Azidohomoalanine 
Methionine - 
auxotrophic 
E.  coli 
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Table 2: Conjugation Chemistries for ADCs.  
R1: protein, e.g., antibody, R2: drug or linker. Please note that many reactions can be performed with reverse location of functional groups 
e.g. tetrazine-charged proteins. Here, we list the most common techniques. For reaction details see 75, 95. 
 
 
Inverse-electron-
demand Diels-
Alder reaction 
 
very fast trans-Cyclooctene-Lysine 
Amber 
suppression 
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